DynamX Bioadaptor: Novel Coronary Prosthesis Enters IDE Trial

Sunday, February 26, 2023

4:22 PM – 4:30 PM ET

Speaker(s)

David Erlinge, MD, PhD (he/him/his)

Professor, Consultant Interventional Cardiology
Lund University
Lund, Sweden

Disclosure(s): Abbott Laboratories, Boston Scientific, Covidien, Janssen Pharmaceuticals, The Medicines Company, Sanofi-Aventis: Advisory Committee/Board Member (Ongoing); AstraZeneca: Clinical Trial Investigator (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bayer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS/Pfizer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sanofi: Scientific Advisory Board (Ongoing)

Disclosure(s):

David Erlinge, MD, PhD: Abbott Laboratories, Boston Scientific, Covidien, Janssen Pharmaceuticals, The Medicines Company, Sanofi-Aventis: Advisory Committee/Board Member (Ongoing); AstraZeneca: Clinical Trial Investigator (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bayer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS/Pfizer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sanofi: Scientific Advisory Board (Ongoing)